Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Introduction

This is a podcast from the Nuffield Department of Medicine (NDM). We've asked Manuel Rivas from Nicaragua and the United States, why he decided to do a DPhil project in the Nuffield Department of Medicine. He also talks about his research and his experience living in Oxford.

MR: I decided to come to Oxford to do a DPhil project, because I thought that it provided a great place to continue the research that I was doing before in Boston, Massachusetts at the Broad Institute after graduating from MIT undergrad. The level of expertise here at Oxford in the statistics field, and in the department of medicine provided a great combination of both worlds.

My research focuses on identifying DNA mutations that predispose you to disease. So currently we're focusing on type 2 diabetes, early onset heart attack, Crohn's disease, and breast cancer. The idea is that with the availability of next generation sequencing technologies, we'll be able to screen the entire genome for rare and low frequency mutations that might be involved the etiology of disease.

Life at oxford, I am currently involved in the Oxford entrepreneurship competition at Oxford, and I’m also involved with the Clarendon scholarship programme. Currently I live off campus at Oxford with my wife, and we enjoy our time by travelling to London and to Bath.

To anyone considering studentship, I'd highly recommend. The NDM programme and the NDM department at Oxford strongly encourages internal and external collaboration. Currently, I'm involved with collaboration with folks from United States, from Switzerland and other groups and departments from the rest of the world, which is an opportunity that really wouldn't be afforded by any other programme I can imagine.